Our plan & strategy
Neuro-SysMed will organize and conduct randomized clinical treatment trials to evaluate efficacy and safety of novel therapies or established therapies with new indications that may delay or even arrest disease progression, ameliorate symptoms or optimize care for affected individuals.
While each study will have its own scientific questions and efficacy endpoints, all projects running under the centre will contribute data, such as clinical scorings, DNA, blood and cerebrospinal fluid analyses, and brain images, to a common Neuro-SysMed database. Using this database, we will integrate the vast amount of information collected at the Centre, in order to define biomarkers that enable early and precise diagnosis, subgrouping of patients within each disease, accurate prognosis and tailored treatment choices for individual patients (i.e. personalized medicine). Thus, Neuro-SysMed aims to development early and improved treatment strategies for patients with serious diseases of the central nervous system.
Randomized clinical trials are the backbone of the centre activities, and cannot be started at a meaningful scale with the NRC funding alone. Consequently, the centre staff made a large effort during 2019 to secure addition external funding for trials.